{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,17]],"date-time":"2026-11-17T13:56:52Z","timestamp":1794923812685,"version":"4.9.1"},"reference-count":48,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["ajo.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["American Journal of Ophthalmology"],"published-print":{"date-parts":[[2023,3]]},"DOI":"10.1016\/j.ajo.2022.10.020","type":"journal-article","created":{"date-parts":[[2022,11,4]],"date-time":"2022-11-04T12:09:05Z","timestamp":1667563745000},"page":"170-180","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"special_numbering":"C","title":["Neurodevelopmental Outcomes for Retinopathy of Prematurity: A Taiwan Premature Infant Follow-up Network Database Study"],"prefix":"10.1016","volume":"247","author":[{"given":"Ming-Chou","family":"Chiang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yen-Ting","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6814-6530","authenticated-orcid":false,"given":"Eugene Yu-Chuan","family":"Kang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4994-8391","authenticated-orcid":false,"given":"Kuan-Jen","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6277-9879","authenticated-orcid":false,"given":"Nan-Kai","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9382-4858","authenticated-orcid":false,"given":"Yen-Po","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2744-3234","authenticated-orcid":false,"given":"Yih-Shiou","family":"Hwang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chi-Chun","family":"Lai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3760-7255","authenticated-orcid":false,"given":"Wei-Chi","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ajo.2022.10.020_bib0001","doi-asserted-by":"crossref","first-page":"1024","DOI":"10.1038\/nm1095-1024","article-title":"Vascular endothelial growth factor acts as a survival factor for newly formed retinal vessels and has implications for retinopathy of prematurity","volume":"1","author":"Alon","year":"1995","journal-title":"Nat Med"},{"key":"10.1016\/j.ajo.2022.10.020_bib0002","doi-asserted-by":"crossref","first-page":"5177","DOI":"10.1167\/iovs.08-2584","article-title":"Through the eyes of a child: understanding retinopathy through ROP the Friedenwald lecture","volume":"49","author":"Smith","year":"2008","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"10.1016\/j.ajo.2022.10.020_bib0003","doi-asserted-by":"crossref","first-page":"1684","DOI":"10.1001\/archopht.121.12.1684","article-title":"Revised indications for the treatment of retinopathy of prematurity: results of the early treatment for retinopathy of prematurity randomized trial","volume":"121","year":"2003","journal-title":"Arch Ophthalmol"},{"key":"10.1016\/j.ajo.2022.10.020_bib0004","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1056\/NEJMoa1007374","article-title":"Efficacy of intravitreal bevacizumab for stage 3+ retinopathy of prematurity","volume":"364","author":"Mintz-Hittner","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ajo.2022.10.020_bib0005","doi-asserted-by":"crossref","first-page":"2366","DOI":"10.1097\/IAE.0000000000002754","article-title":"Anatomical and functional results of intravitreal aflibercept monotherapy for type 1 retinopathy of prematurity: one-year outcomes","volume":"40","author":"Chen","year":"2020","journal-title":"Retina"},{"key":"10.1016\/j.ajo.2022.10.020_bib0006","doi-asserted-by":"crossref","first-page":"1551","DOI":"10.1016\/S0140-6736(19)31344-3","article-title":"Ranibizumab versus laser therapy for the treatment of very low birthweight infants with retinopathy of prematurity (RAINBOW): an open-label randomised controlled trial","volume":"394","author":"Stahl","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.ajo.2022.10.020_bib0007","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1136\/bjophthalmol-2017-311662","article-title":"Efficacy of intravitreal conbercept injection in the treatment of retinopathy of prematurity","volume":"103","author":"Bai","year":"2019","journal-title":"Br J Ophthalmol"},{"key":"10.1016\/j.ajo.2022.10.020_bib0008","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1007\/s00417-018-4168-5","article-title":"Comparison of clinical outcomes of intravitreal ranibizumab and aflibercept treatment for retinopathy of prematurity","volume":"257","author":"Sukgen","year":"2019","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"issue":"8","key":"10.1016\/j.ajo.2022.10.020_bib0009","doi-asserted-by":"crossref","first-page":"1532","DOI":"10.1038\/s41433-021-01922-2","article-title":"The role of anti-vascular endothelial growth factor in treatment of retinopathy of prematurity\u2013a current review","volume":"36","author":"Chow","year":"2022","journal-title":"Eye (Lond)"},{"key":"10.1016\/j.ajo.2022.10.020_bib0010","article-title":"Anti-vascular endothelial growth factor (VEGF) drugs for treatment of retinopathy of prematurity","volume":"1","author":"Sankar","year":"2018","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.ajo.2022.10.020_bib0011","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.ajo.2018.05.002","article-title":"Macular structures, optical components, and visual acuity in preschool children after intravitreal bevacizumab or laser treatment","volume":"192","author":"Lee","year":"2018","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.ajo.2022.10.020_bib0012","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1001\/jamaophthalmol.2014.2772","article-title":"Refractive outcomes following bevacizumab monotherapy compared with conventional laser treatment: a randomized clinical trial","volume":"132","author":"Geloneck","year":"2014","journal-title":"JAMA Ophthalmol"},{"key":"10.1016\/j.ajo.2022.10.020_bib0013","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1016\/j.ajo.2011.07.005","article-title":"Serum concentrations of bevacizumab (avastin) and vascular endothelial growth factor in infants with retinopathy of prematurity","volume":"153","author":"Sato","year":"2012","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.ajo.2022.10.020_bib0014","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1007\/s00417-017-3878-4","article-title":"Changes in systemic vascular endothelial growth factor levels after intravitreal injection of aflibercept in infants with retinopathy of prematurity","volume":"256","author":"Huang","year":"2018","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"10.1016\/j.ajo.2022.10.020_bib0015","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1097\/IAE.0000000000001209","article-title":"Serum vascular endothelial growth factor after bevacizumab or ranibizumab treatment for retinopathy of prematurity","volume":"37","author":"Wu","year":"2017","journal-title":"Retina"},{"key":"10.1016\/j.ajo.2022.10.020_bib0016","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1001\/jamaophthalmol.2014.5373","article-title":"Serum levels of vascular endothelial growth factor and related factors after intravitreous bevacizumab injection for retinopathy of prematurity","volume":"133","author":"Wu","year":"2015","journal-title":"JAMA Ophthalmol"},{"key":"10.1016\/j.ajo.2022.10.020_bib0017","doi-asserted-by":"crossref","DOI":"10.1155\/2019\/2985161","article-title":"Serum vascular endothelial growth factor levels before and after intravitreous ranibizumab injection for retinopathy of prematurity","volume":"2019","author":"Chen","year":"2019","journal-title":"J Ophthalmol"},{"key":"10.1016\/j.ajo.2022.10.020_bib0018","doi-asserted-by":"crossref","first-page":"220","DOI":"10.3928\/23258160-20200326-03","article-title":"Neurodevelopmental outcomes following intravitreal bevacizumab with laser versus laser photocoagulation alone for retinopathy of prematurity","volume":"51","author":"Ahmed","year":"2020","journal-title":"Ophthalmic Surg Lasers Imaging Retina"},{"key":"10.1016\/j.ajo.2022.10.020_bib0019","doi-asserted-by":"crossref","first-page":"585","DOI":"10.3109\/02713683.2014.941070","article-title":"Preliminary anatomical and neurodevelopmental outcomes of intravitreal bevacizumab as adjunctive treatment for retinopathy of prematurity","volume":"40","author":"Araz-Ersan","year":"2015","journal-title":"Curr Eye Res"},{"key":"10.1016\/j.ajo.2022.10.020_bib0020","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0230678","article-title":"Neurodevelopmental outcomes following intravitreal bevacizumab injection in Japanese preterm infants with type 1 retinopathy of prematurity","volume":"15","author":"Arima","year":"2020","journal-title":"PLoS One"},{"key":"10.1016\/j.ajo.2022.10.020_bib0021","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0223972","article-title":"Involution of retinopathy of prematurity and neurodevelopmental outcomes after intravitreal bevacizumab treatment","volume":"14","author":"Chang","year":"2019","journal-title":"PLoS One"},{"key":"10.1016\/j.ajo.2022.10.020_bib0022","doi-asserted-by":"crossref","first-page":"126","DOI":"10.3928\/23258160-20180129-07","article-title":"Outcomes of intravitreal bevacizumab and diode laser photocoagulation for treatment-warranted retinopathy of prematurity","volume":"49","author":"Chen","year":"2018","journal-title":"Ophthalmic Surg Lasers Imaging Retina"},{"key":"10.1016\/j.ajo.2022.10.020_bib0023","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.ajo.2021.06.034","article-title":"Cognitive outcomes following intravitreal bevacizumab for retinopathy of prematurity: 4- to 6-year outcomes in a prospective cohort","volume":"234","author":"Chou","year":"2022","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.ajo.2022.10.020_bib0024","doi-asserted-by":"crossref","first-page":"1567","DOI":"10.1016\/j.ophtha.2019.03.048","article-title":"Neurodevelopmental outcomes after intravitreal bevacizumab therapy for retinopathy of prematurity: a prospective case-control study","volume":"126","author":"Fan","year":"2019","journal-title":"Ophthalmology"},{"key":"10.1016\/j.ajo.2022.10.020_bib0025","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.1038\/s41372-020-00884-9","article-title":"Neurodevelopmental outcomes following bevacizumab treatment for retinopathy of prematurity: a systematic review and meta-analysis","volume":"41","author":"Kaushal","year":"2021","journal-title":"J Perinatol"},{"key":"10.1016\/j.ajo.2022.10.020_bib0026","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.jaapos.2017.10.006","article-title":"Medical and developmental outcomes of bevacizumab versus laser for retinopathy of prematurity","volume":"22","author":"Kennedy","year":"2018","journal-title":"J AAPOS"},{"key":"10.1016\/j.ajo.2022.10.020_bib0027","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0148019","article-title":"Neurodevelopmental outcomes in infants with retinopathy of prematurity and bevacizumab treatment","volume":"11","author":"Lien","year":"2016","journal-title":"PLoS One"},{"key":"10.1016\/j.ajo.2022.10.020_bib0028","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1097\/IAE.0b013e318275394a","article-title":"Long-term effect of antiangiogenic therapy for retinopathy of prematurity up to 5 years of follow-up","volume":"33","author":"Martinez-Castellanos","year":"2013","journal-title":"Retina"},{"key":"10.1016\/j.ajo.2022.10.020_bib0029","first-page":"137","article-title":"Neurodevelopmental outcomes following bevacizumab injections for retinopathy of prematurity","author":"Morin","year":"2016","journal-title":"Pediatrics"},{"key":"10.1016\/j.ajo.2022.10.020_bib0030","first-page":"144","article-title":"Neurodevelopmental outcomes of preterm infants with retinopathy of prematurity by treatment","author":"Natarajan","year":"2019","journal-title":"Pediatrics"},{"key":"10.1016\/j.ajo.2022.10.020_bib0031","doi-asserted-by":"crossref","first-page":"1300","DOI":"10.1038\/s41372-019-0420-z","article-title":"Neurodevelopmental outcomes in infants treated with intravitreal bevacizumab versus laser","volume":"39","author":"Raghuram","year":"2019","journal-title":"J Perinatol"},{"key":"10.1016\/j.ajo.2022.10.020_bib0032","doi-asserted-by":"crossref","first-page":"337","DOI":"10.3928\/23258160-20190605-01","article-title":"Neurodevelopmental outcomes comparing bevacizumab to laser for type 1 ROP","volume":"50","author":"Rodriguez","year":"2019","journal-title":"Ophthalmic Surg Lasers Imaging Retina"},{"key":"10.1016\/j.ajo.2022.10.020_bib0033","doi-asserted-by":"crossref","first-page":"e91","DOI":"10.1111\/aos.14852","article-title":"Ranibizumab in retinopathy of prematurity\u2013one-year follow-up of ophthalmic outcomes and two-year follow-up of neurodevelopmental outcomes from the CARE-ROP study","volume":"100","author":"Stahl","year":"2022","journal-title":"Acta Ophthalmol"},{"key":"10.1016\/j.ajo.2022.10.020_bib0034","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1016\/j.survophthal.2021.02.012","article-title":"Neurodevelopmental outcomes in preterm infants with retinopathy of prematurity","volume":"66","author":"Tan","year":"2021","journal-title":"Surv Ophthalmol"},{"key":"10.1016\/j.ajo.2022.10.020_bib0035","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1016\/j.ophtha.2020.11.012","article-title":"Neurodevelopmental outcomes after bevacizumab treatment for retinopathy of prematurity: a meta-analysis","volume":"128","author":"Tsai","year":"2021","journal-title":"Ophthalmology"},{"issue":"2","key":"10.1016\/j.ajo.2022.10.020_bib0036","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1097\/ANC.0000000000000881","article-title":"Neurodevelopmental outcomes associated with intravitreal bevacizumab injections for retinopathy of prematurity","volume":"22","author":"Webb","year":"2021","journal-title":"Adv Neonatal Care"},{"key":"10.1016\/j.ajo.2022.10.020_bib0037","doi-asserted-by":"crossref","first-page":"1158","DOI":"10.1055\/s-0040-1710556","article-title":"Bevacizumab for retinopathy of prematurity: 2-year neurodevelopmental follow-up","volume":"38","author":"Zayek","year":"2021","journal-title":"Am J Perinatol"},{"key":"10.1016\/j.ajo.2022.10.020_bib0038","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.pedneo.2019.05.006","article-title":"Neurodevelopmental outcomes at 2 and 5 years of age in very-low-birth-weight preterm infants born between 2002 and 2009: a prospective cohort study in Taiwan","volume":"61","author":"Lin","year":"2020","journal-title":"Pediatr Neonatol"},{"key":"10.1016\/j.ajo.2022.10.020_bib0039","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1016\/j.pedneo.2019.03.004","article-title":"Risk factors for postdischarge growth retardation among very-low-birth-weight infants: a nationwide registry study in Taiwan","volume":"60","author":"Liao","year":"2019","journal-title":"Pediatr Neonatol"},{"key":"10.1016\/j.ajo.2022.10.020_bib0040","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1016\/j.jfma.2016.10.011","article-title":"Morbidity and mortality of very low birth weight infants in Taiwan\u2013changes in 15 years: a population based study","volume":"115","author":"Su","year":"2016","journal-title":"J Formos Med Assoc"},{"key":"10.1016\/j.ajo.2022.10.020_bib0041","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1136\/archdischild-2020-319063","article-title":"How to use the Bayley Scales of Infant and Toddler Development","volume":"106","author":"Del Rosario","year":"2021","journal-title":"Arch Dis Child Educ Pract Ed"},{"key":"10.1016\/j.ajo.2022.10.020_bib0042","doi-asserted-by":"crossref","first-page":"e74","DOI":"10.1016\/j.ophtha.2017.05.007","article-title":"Re: Good: Bevacizumab for retinopathy of prematurity: treatment when pathology is embedded in a normally developing vascular system (Ophthalmology. 2016;123:1843-1844)","volume":"124","author":"Blair","year":"2017","journal-title":"Ophthalmology"},{"key":"10.1016\/j.ajo.2022.10.020_bib0043","doi-asserted-by":"crossref","first-page":"1202","DOI":"10.1016\/j.oret.2020.06.002","article-title":"A comparison of respiratory outcomes after treating retinopathy of prematurity with laser photocoagulation or intravitreal bevacizumab","volume":"4","author":"Barry","year":"2020","journal-title":"Ophthalmol Retina"},{"key":"10.1016\/j.ajo.2022.10.020_bib0044","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1038\/pr.2015.106","article-title":"Impaired cognitive performance in premature newborns with two or more surgeries prior to term-equivalent age","volume":"78","author":"Gano","year":"2015","journal-title":"Pediatr Res"},{"key":"10.1016\/j.ajo.2022.10.020_bib0045","doi-asserted-by":"crossref","first-page":"e85760","DOI":"10.1371\/journal.pone.0085760","article-title":"Current clinical evidence on the effect of general anesthesia on neurodevelopment in children: an updated systematic review with meta-regression","volume":"9","author":"Wang","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.ajo.2022.10.020_bib0046","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1016\/j.jpeds.2011.09.009","article-title":"Neurologic outcomes in very preterm infants undergoing surgery","volume":"160","author":"Filan","year":"2012","journal-title":"J Pediatr"},{"key":"10.1016\/j.ajo.2022.10.020_bib0047","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1038\/s41390-020-1030-3","article-title":"Surgery requiring general anesthesia in preterm infants is associated with altered brain volumes at term equivalent age and neurodevelopmental impairment","volume":"89","author":"Walsh","year":"2021","journal-title":"Pediatr Res"},{"key":"10.1016\/j.ajo.2022.10.020_bib0048","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1016\/j.ajo.2012.06.010","article-title":"An updated study of the use of bevacizumab in the treatment of patients with prethreshold retinopathy of prematurity in Taiwan","volume":"155","author":"Wu","year":"2013","journal-title":"Am J Ophthalmol"}],"container-title":["American Journal of Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002939422004160?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002939422004160?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,11]],"date-time":"2025-09-11T13:51:58Z","timestamp":1757598718000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0002939422004160"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3]]},"references-count":48,"alternative-id":["S0002939422004160"],"URL":"https:\/\/doi.org\/10.1016\/j.ajo.2022.10.020","relation":{},"ISSN":["0002-9394"],"issn-type":[{"value":"0002-9394","type":"print"}],"subject":[],"published":{"date-parts":[[2023,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Neurodevelopmental Outcomes for Retinopathy of Prematurity: A Taiwan Premature Infant Follow-up Network Database Study","name":"articletitle","label":"Article Title"},{"value":"American Journal of Ophthalmology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ajo.2022.10.020","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}